9/16/2013

The FDA has awarded the breakthrough therapy designation to GlaxoSmithKline's chronic lymphocytic leukemia drug Arzerra, or ofatumumab. The status covers use in combination with chlorambucil when fludarabine-based therapy is not an option.

Related Summaries